Diagnosed days before hosting 100K country music fans
Sarah Trahern is CEO of the Country Music Association (CMA). Read her T1D story.
We are Breakthrough T1D
As the leading global type 1 diabetes (T1D) research and advocacy organization, we’re here to make every day life with T1D better.
C-Peptide as an Endpoint in Clinical Trials: Its Time Has Come
A new publication provides more evidence for C-peptide as a validated surrogate to predict clinical benefits of disease-modifying therapies in T1D.
A New Shot on Goal for Cell Therapies In T1D
Eledon Pharmaceuticals announces new funding from the T1D Fund and the launch of their clinical trial for tegoprubart in T1D.
Beating the Odds: The Improbable Story of How Perseverance, Belief, and Luck Led to the Approval of the First Life-Changing Immune Therapy for Type 1 Diabetes
The true story of how Tzield (teplizumab), the first disease-modifying therapy approved for use in delaying type 1 diabetes (T1D) onset, made it to market.
ATTD Brings Together Top Minds in Diabetes Research
Leading researchers gathered for the ATTD meeting, which featured more than 50 studies presented by Breakthrough T1D-funded researchers.
Top Researchers Gather for the 17th ATTD Conference
This year’s Advanced Technologies & Treatments for Diabetes (ATTD) meeting, which will be held on March 6-9, will have 50 Breakthrough T1D-funded presenters.
Breakthrough T1D T1D Fund Invests in vTv Therapeutics
With an investment from the Breakthrough T1D T1D Fund, vTv Therapeutics will run a phase III clinical trial of cadisegliatin (TTP399), an adjunct therapy to insulin.
World-Renowned Researchers Gather at the Breakthrough T1D-nPOD Annual Meeting
Leading researchers gathered in Long Beach, California, for the 16th annual meeting of the Network for Pancreatic Organ Donors with Diabetes (nPOD).
Bench to Bedside: Breakthrough T1D-nPOD Conference
Leading scientists will gather for the annual meeting of the Network for Pancreatic Organ Donors with Diabetes (nPOD), held February 19-22 in California.
